Insider · CIK 0001213041
Elizabeth A Grammer
Files at SGMT (Sagimet Biosciences Inc.), ARDX (ARDELYX, INC.). First filing Nov 22, 2024, latest Aug 25, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARDX: ARDELYX, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | ARDELYX, INC. | $35k 5,841 shares | -2% | +86% from low-12% from high | |
| 30Weak | ARDELYX, INC. | $24k 5,992 shares | -2% | +27% from low-40% from high | |
| 30Weak | ARDELYX, INC. | $24k 4,291 shares | -2% | +27% from low-17% from high | |
| 36Weak | ARDELYX, INC. | $34k 7,046 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -5,841 | $5.93 | $35k | 305,890 | Aug 25, 2025 |
| Jun 9, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| May 20, 2025 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -5,992 | $4.08 | $24k | 311,731 | May 22, 2025 |
| Feb 25, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +136,680 | $0.00 | $0 | 317,723 | Feb 27, 2025 |
| Feb 25, 2025 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +205,019 | $0.00 | $0 | 205,019 | Feb 27, 2025 |
| Feb 20, 2025 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -4,291 | $5.62 | $24k | 181,043 | Feb 21, 2025 |
| Nov 20, 2024 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -7,046 | $4.79 | $34k | 185,334 | Nov 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.